CDKL5 and craniodiaphyseal dysplasia: Here, by combining the cell-penetrating property of our recently developed TATk-CDKL5 fusion construct with a secretory Igk-chain leader sequence and the advantages of a gene therapy approach, we have developed a new therapeutic approach that is able to overcome the limitations of both gene therapy and ERT for CDD.